A bispecific monoclonal antibody directed against both the membrane- bound complement regulator CD55 and the renal tumor-associated antigen G250 enhances C3 deposition and tumor cell lysis by complement

Journal of Immunology

Volumn 160, Issue 7, 1998, Pages 3437-3443

  Blok, Vanessa T ^a   Daha, Mohamed R ^a   Tijsma, Odette ^a   Harris, Claire L ^b   Morgan, B Paul ^b   Fleuren, Gert Jan ^a   Gorter, Arko ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; DECAY ACCELERATING FACTOR; MONOCLONAL ANTIBODY;

ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; CANCER INHIBITION; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; CYTOLYSIS; HUMAN; HUMAN CELL; IMMUNOREGULATION; KIDNEY TUMOR; OPSONIZATION; PRIORITY JOURNAL;

ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD55; ANTIGENS, NEOPLASM; CELL MEMBRANE; CLONE CELLS; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT INACTIVATOR PROTEINS; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; KIDNEY NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0032055874     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Pittman, K., and P. Selby. 1994. The management of renal cell carcinoma. Crit. Rev. Oncol. Hematol. 16:181.
2. Taneja, S. S., W. Pierce, R. Figlin, and A. Belldegrun. 1995. Immunotherapy for renal cell carcinoma: the era of interleukin-2-based treatment. Urology 45:911.
3. Fyfe, G., R. I. Fisher, S. A. Rosenberg, M. Sznol, D. R. Parkinson, and A. C. Louie. 1995. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13:688.
4. Hrouda, D., G. H. Muir, and A. G. Dalgleish. 1997. The role of immunotherapy for urological tumours. Brit. J. Urol. 79:307.
5. Oosterwijk, E., F. M. J. Debruyne, and J. A. Schalken. 1995. The use of monoclonal antibody G250 in the therapy of renal-cell carcinoma. Semin. Oncol. 22: 34.
6. Steffens, M. G., O. C. Boerman, J. C. Oosterwijk-Wakka, G. O. N. Oosterhof, J. A. Witjes, E. B. Koenders, W. J. G. Oyen, W. C. A. M. Buijs, F. M. J. Debruyne, F. H. M. Corstens, and E. Oosterwijk. 1997. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J. Clin. Oncol. 15:1529.
7. Oosterwijk, E., N. H. Bander, C. R. Divgi, S. Welt, J. C. Wakka, R. D. Finn, E. A. Carswell, S. M. Larson, S. O. Warnaar, G. J. Fleuren, H. F. Oettgen, and L. J. Old. 1993. Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J. Clin. Oncol. 11:738.
8. Dillman, R. O. 1994. Antibodies as cytotoxic therapy. J. Clin. Oncol. 12:1497.
9. Morgan, B. P., and S. Meri. 1994. Membrane proteins that protect against complement lysis. Springer Semin. Immunopathol. 15:369.
10. Seya, T., M. Matsumoto, and H. Akedo. 1990. Quantitative analysis of membrane cofactor protein (MCP) of complement: high expression of MCP on human leukemia cell lines, which is down-regulated during cell differentiation. J. Immunol. 145:238.
11. Kumar, S., J. M. Vinci, B. A. Pytel, and C. Baglioni. 1993. Expression of messenger RNAs for complement inhibitors in human tissues and tumors. Cancer Res. 53:348.
12. Bjørge, L., C. A. Vedeler, E. Ulvestad, and R. Matre. 1994. Expression and function of CD59 on colonic adenocarcinoma cells. Eur. J. Immunol. 24:1597.
13. Hofman, P., B.-L. Hsi, S. Manie, P. Fenichel, A. Thyss, and B. Rossi. 1994. High expression of the antigen recognized by the monoclonal antibody GB24 on human breast carcinomas: a preventive mechanism of malignant tumor cells against complement attack. Breast Cancer Res. Treat. 32:213.
14. Mäenpää, A., S. Junnikkala, J. Hakulinen, T. Timonen, and S. Meri. 1996. Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas. Am. J. Pathol. 148:1139.
15. Nicholson-Weller, A., and C. Wang. 1994. Structure and function of decay accelerating factor CD55. J. Lab. Clin. Med. 123:485.
16. Oosterwijk, E., D. J. Ruiter, P. J. Hoedemaeker, E. K. J. Pauwels, U. Jonas, J. Zwartendijk, and S. O. Warnaar. 1986. Monoclonal antibody G250 recognizes a determinant present in renal cell carcinoma and absent from normal kidney. Int. J. Cancer 38:489.
17. Van Dijk, J., S. O. Warnaar, J. D. H. Van Eendenburg, M. Thienpont, E. Braakman, J. H. A. Boot, G. J. Fleuren, and R. L. H. Bolhuis. 1989. Induction of tumor cell lysis by bispecific monoclonal antibodies recognizing renal cell carcinoma and CD3 antigen. Int. J. Cancer 43:344.
18. Corver, W. E., C. J. Cornelisse, J. Hermans, and G. J. Fleuren. 1995. Limited loss of nine tumor-associated surface antigenic determinants after tryptic cell dissociation. Cytometry 19:267.
19. Milstein, C., and A. C. Cuello. 1984. Hybrid hybridomas and the production of bi-specific monoclonal antibodies. Immunol. Today 5:299.
20. Gorter, A., V. T. Blok, W. H. B. Haasnoot, N. G. Ensink, M. R. Daha, and G. J. Fleuren. 1996. Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complemented-mediated tumor cell lysis. Lab. Invest. 74:1039.
21. Bono, A. V., and J. A. J. Lovisolo. 1997. Renal cell carcinoma - diagnosis and treatment: state of the art. Eur. Urol. 31:47.
22. Niehans, G. A., D. L. Cherwitz, N. A. Staley, D. J. Knapp, and A. P. Dalmasso. 1996. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am. J. Pathol. 149:129.
23. Matsuo, S., S. Ichida, H. Takizawa, N. Okada, L. Baranyi, A. Iguchi, B. P. Morgan, and H. Okada. 1994. In vivo effects of monoclonal antibodies that functionally inhibit complement regulatory proteins in rats. J. Exp. Med. 180: 1619.
24. Nomura, A., K. Nishikawa, Y. Yuzawa, H. Okada, N. Okada, B. P. Morgan, S. J. Piddlesden, M. Nadai, T. Hasegawa, and S. Matsuo. 1995. Tubulointerstitial injury induced in rats by a monoclonal antibody that inhibits function of a membrane inhibitor of complement. J. Clin. Invest. 96:2348.
25. Seya, T., M. Okada, M. Matsumoto, K. Hong, T. Kinoshita, and J. P. Atkinson. 1991. Preferential inactivation of the C5 convertase of the alternative complement pathway by factor I and membrane cofactor protein (MCP). Mol. Immunol. 28:1137.
26. Kojima, A., K. Iwata, T. Seya, M. Matsumoto, H. Ariga, J. P. Atkinson, and S. Nagasawa. 1993. Membrane cofactor protein (CD46) protects cells predominantly from alternative complement pathway-mediated C3-fragment deposition and cytolysis. J. Immunol. 151:1519.
27. Seya, T., A. Kojima, T. Hara, K. Hazeki, Y. Sugita, and H. Akedo. 1991. Enhancement of lymphocyte-mediated K562 cytotoxicity by antibodies against complement membrane cofactor protein (CD46) and decay-accelerating factor (CD55). Immunobiology 183:115.
28. Junnikkala, S., J. Hakulinen, and S. Meri. 1994. Targeted neutralization of the complement membrane attack complex inhibitor CD59 on the surface of human melanoma cells. Eur. J. Immunol. 24:611.
29. Harris, C. L., K. S. Kan, G. T. Stevenson, and B. P. Morgan. 1997. Tumour cell killing using chemically engineered antibody constructs specific for tumour cells and the complement inhibitor CD59. Clin. Exp. Immunol. 107:364.
30. Hara, T., Kojima, A., Fukuda, H., Masaoka, T., Fukumori, Y., Matsumoto, M., and Seya, T. 1992. Levels of complement regulatory proteins, CD35 (CR1), CD46 (MCP) and CD55 (DAF) in human haematological malignancies. Br. J. Haematol. 82:368.
31. Seelen, M. A. J., R. A. Brooimans, F. J. Van der Woude, L. A. Van Es, and M. R. Daha. 1993. IFN-gamma mediates stimulation of complement C4 biosynthesis in human proximal tubular epithelial cells. Kidney Int. 44:50.
32. Gerritsma, J. S. J., A. F. Gerritsen, C. Van Kooten, L. A. Van Es, and M. R. Daha. 1996. Interleukin-1α enhances the biosynthesis of complement C3 and factor B by human kidney proximal tubular epithelial cells in vitro. Mol. Immunol. 33:847.
33. Morgan, B. P., and P. Gasque. 1997. Extrahepatic complement biosynthesis: where, when and why? Clin. Exp. Immunol. 107:1.
34. Juni, H., F. Helmig, K. Baltzer, H. Kalthoff, D. Henne-Bruns, and B. Kremer. 1997. Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A. J. Surg. Oncol. 64:222.